UNCLAIMED
CellCarta
Overview
CellCarta is a Canadian company operating in the business services sector, specifically focusing on research and development within the biopharmaceutical industry. Established in 2002, the company specializes in precision medicine services, particularly through the application of advanced genomic technologies such as RNA sequencing (RNA-seq) and digital pathology. Their document corpus includes technical reports and case studies that detail their methodologies and findings related to whole transcriptome sequencing, biomarker testing, and the evaluation of digital pathology systems. For example, their case studies highlight the challenges and solutions associated with RNA-seq from clinical specimens, emphasizing improvements in turnaround time and data quality. Additionally, CellCarta's technical reports present performance evaluations of various assays, including those for non-small cell lung cancer (NSCLC), showcasing their capabilities in handling low input materials and enhancing assay sensitivity. The company's publications reflect a commitment to addressing complex challenges in translational research and clinical applications, underscoring their expertise in biomarker discovery and precision medicine.